2025-05-26 | Irene, EffePharm
May 20–22, 2025, EffePharm, a global leader in healthy aging and nutritional biotechnology, captivated attendees at Vitafoods Europe 2025 in Barcelona. Showcasing groundbreaking advancements in NAD+ research and nutrient delivery systems for improved dietary supplements, EffePharm solidified its position as a pioneer in scientifically validated anti-aging solutions. Here’s a deep dive into their latest breakthroughs and strategic vision.

EffePharm’s NAD+ Booster Series stole the spotlight, offering tangible solutions to age-related NAD+ supplementation—a key driver of cellular aging.
UTHEVER® NMN is the world’s first clinically proven NMN brand. It is now positioned to become the first NMN ingredient to secure EU Novel Food certification. UTHEVER® is currently in the final review stage with the European Food Safety Authority (EFSA). Its impending approval paves the way for EU market entry, with multiple brands already securing pre-orders to capitalize on this regulatory milestone.
Learn more about the NMN Novel Food Updates.
Backed by the world’s first double-blind human trial, UthPeak® demonstrated a 3x increase in NAD+ levels and a maximum 5-year reversal in biological age after 90 days of supplementation. Being EffePharm’s premium NAD+ enhancer, its safety has already been validated by Self-GRAS certification. In the first phase clinical trial results, it also showed significant improvements in energy levels (+35%) and emotional well-being (+31%).
EffePharm’s proprietary LipoAvail™ liposomal technology addresses bioavailability challenges, ensuring active ingredients reach their targets efficiently:
The LipoAvail™ liposomal technology not only optimizes absorption but also stabilizes sensitive compounds in harsh gastric environments, making it a game-changer for functional nutrition.


EffePharm’s technical seminars drew standing-room-only crowds, featuring insights from
Their presentations underscored EffePharm’s commitment to bridging cutting-edge research with real-world applications, fostering industry-wide consensus on NAD+’s potential.

“Europe isn’t just a checkbox on our global map—it’s the heartbeat of our mission to make aging healthier for everyone,” said Dr. Jianjun Yu. At EffePharm, we’ve built our approach on three interconnected foundations: innovative ingredients, smarter formulations, and real-world proof. Together, they form a living framework designed to turn lab breakthroughs into solutions that resonate with everyday lives.

Reference available upon request.
| These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. |
Information on this site is provided for informational purposes only. It is not meant to substitute for medical advice from your physician or other medical professional. You should not use the information contained herein to diagnose or treat a health problem or disease or prescribe any medication. Carefully read all product documentation. If you have or suspect that you have a medical problem, promptly contact your regular healthcare provider.